Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Coghill Capital Management Maintains Stake In General Moly, Inc. (GMO), No Longer Activist

Clint Coghill’s Coghill Capital Management, a small-cap value investing advisor, has maintained its stake in General Moly, Inc. (NYSEMKT:GMO) as per its recent 13G filing with the SEC. The investment manager reported ownership of 4.84 million shares of the mineral company, representing 5.1% of the company’s common shares. Coghill first disclosed a stake in General Moly, Inc. (NYSEMKT:GMO) at the end of the fourth quarter of 2007 of 10.53 million shares valued at $122.88 million. Coghill has not filed a 13F with the SEC since the September 30, 2014 filing period, and has not filed on General Moly since a 13D filing near the end of that year. The latest filing shows that Coghill’s position in the company is no longer activist.


Clint Coghill founded Coghill Capital Management in 1995 with a focus on small-cap value equity management. The Chicago-based investment firm provides money management services to foundations, family offices, pension plans, endowments, institutional investors, and high-worth professionals. The fund manager is known to target small-cap companies, providing healthy returns to its investors. Coghill Capital Management last reported a public equity portfolio of $3.63 million at the end of the third quarter of 2014.

Clint Coghill
Clint Coghill
Coghill Capital Management

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically delivered a monthly alpha of six basis points, though these stocks underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning over 139% and beating the market by more than 80 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise rather than large-cap stocks.

General Moly, Inc. (NYSEMKT:GMO) is a mineral development company headquartered in Lakewood, Colorado. The firm is working on two major molybdenum projects in Nevada, U.S.A. The mineral company has an 80% stake in the Mt. Hope Project, which is among the largest molybdenum projects in the world, along with a 20% share of POSCO (ADR) (NYSE:PKX). General Moly, Inc. owns another project, Liberty Project, with ores containing both molybdenum and copper.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.